

FINDING OF NO SIGNIFICANT IMPACT

for

Monensin for Turkeys Greater Than 10 Weeks of Age

ENVIRONMENTAL ASSESSMENT
NADA 130-736 C011

FOR THE USE OF
Elanco Products Company
Indianapolis, Indiana

The Center for Veterinary Medicine has carefully considered the potential environmental impact of this action and has concluded that this action will not have a significant effect on the quality of the human environment and that an environmental impact statement therefore will not be prepared.

Elanco has submitted a supplemental new animal drug application which proposes the use of monensin sodium in the feed of turkeys from 10 weeks of age to market. The product is already approved for use in younger growing turkeys. The product will be used for the prevention of coccidiosis at concentrations ranging from 54 to 90 grams monensin per ton of feed (60 to 99 ppm).

In support of their application, the firm has prepared an environmental assessment (dated March 1989, attached) that addresses the potential environmental impacts of manufacturing and using the additional monensin that would be permitted by this action.


We have reviewed the environmental assessment and the label for the product, which contains instructions for the safe use of the product, and have concluded that the proposed action would not be expected to have a significant impact at the sites where the drug is manufactured, where the medicated feed is prepared, and at locations where turkeys are raised.

Eli Lilly Corporate Center
Indianapolis, Indiana 46285

8/7/89
Date


Primary Action Officer, HFV-135

8/7/89
Date


Preparer and Chief,
Environmental Sciences Staff, HFV-162

cc: Orig. & Dup., (NADA 130-736 C011)
Office File, HFV-162
Reading Board, HFV-162